Xagenic secures $1 million investment in chip-based technology for detecting disease, cancer and infection
MaRS Innovation, HTX, OICR and CCR commit over $1 million to speed commercialization of a new rapid molecular diagnostic technology.
MaRS Innovation, HTX, OICR and CCR commit over $1 million to speed commercialization of a new rapid molecular diagnostic technology.